Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Convertible Debt (2017 - 2025)

Guided Therapeutics (GTHP) has disclosed Convertible Debt for 12 consecutive years, with $35000.0 as the latest value for Q1 2025.

  • Quarterly Convertible Debt fell 96.9% to $35000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $35000.0 through Mar 2025, down 96.9% year-over-year, with the annual reading at $14000.0 for FY2024, N/A changed from the prior year.
  • Convertible Debt hit $35000.0 in Q1 2025 for Guided Therapeutics, up from $14000.0 in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $1.1 million in Q1 2024 to a low of $14000.0 in Q4 2024.
  • Historically, Convertible Debt has averaged $620090.9 across 5 years, with a median of $820000.0 in 2021.
  • Biggest five-year swings in Convertible Debt: surged 797.06% in 2021 and later tumbled 96.9% in 2025.
  • Year by year, Convertible Debt stood at $820000.0 in 2021, then increased by 27.56% to $1.0 million in 2022, then dropped by 6.12% to $982000.0 in 2023, then crashed by 98.57% to $14000.0 in 2024, then soared by 150.0% to $35000.0 in 2025.
  • Business Quant data shows Convertible Debt for GTHP at $35000.0 in Q1 2025, $14000.0 in Q4 2024, and $162000.0 in Q3 2024.